# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-10 of 552 results.
Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas
Status: Recruiting
Last Changed: Jan 06, 2020
First Received: Apr 19, 2019
Disease(s): B Cell Lymphomas
Intervention(s): Nivolumab, Microtransplantation
Locations: Duke University, Durham, North Carolina, United States
A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy
Status: Recruiting
Last Changed: Jul 29, 2019
First Received: Jul 29, 2019
Disease(s): B Cell Lymphoma
Intervention(s): CD20-directed CAR-T cells
Locations: Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China
INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)
Status: Recruiting
Last Changed: Feb 12, 2020
First Received: Feb 06, 2018
Disease(s): B-cell Lymphoma
Intervention(s): Parsaclisib, Rituximab, Bendamustine, Ibrutinib
Locations: University of Arizona Cancer Center- Out Pt, Tucson, Arizona, United States
Indiana Blood and Marrow Transplantation, Indianapolis, Indiana, United States
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
Texas Oncology, Austin, Texas, United States
Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
... and 17 other locations.
Quikin CD19-CART in Patients With r/r B-cell Lymphoma
Status: Not yet recruiting
Last Changed: Dec 30, 2019
First Received: Dec 30, 2019
Disease(s): B-cell Lymphoma
Intervention(s): CD19-Specific Chimeric Antigen Receptor T cells with PD1 knockout
Study of TG-1801 in Subjects With B-Cell Lymphoma
Status: Recruiting
Last Changed: Feb 12, 2020
First Received: Jan 15, 2019
Disease(s): B-Cell Lymphoma
Intervention(s): TG-1801
Locations: Olivia Newton-John Cancer Wellness & Research Centre, Heidelberg, Australia
The Alfred Hospital, Melbourne, Australia
TG Therapeutics Investigational Trial Site, Nedlands, Australia
Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma.
Status: Recruiting
Last Changed: Apr 26, 2019
First Received: Apr 26, 2019
Disease(s): B Cell Lymphoma
Intervention(s): Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells
Locations: The first affiliated hospital of Zhejiang University, Hangzhou, Zhejiang, China
Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma
Status: Recruiting
Last Changed: Jan 10, 2020
First Received: Dec 03, 2018
Disease(s): B-cell Lymphoma
Intervention(s): Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide
Locations: Banner Health MD Anderson Cancer Center, Gilbert, Arizona, United States
City of Hope, Duarte, California, United States
UCLA, Los Angeles, California, United States
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
University of Chicago, Chicago, Illinois, United States
... and 6 other locations.
A Study to Investigate BGB-3111 in Chinese Patients With B-cell Lymphoma
Status: Recruiting
Last Changed: Nov 04, 2019
First Received: Jun 16, 2017
Disease(s): B-cell Lymphoma
Intervention(s): BGB-3111
Locations: Beijing Cancer Hospital, Beijing, Beijing, China
Tongji Hospital, Tongji Medical College Huazhong Univ of Sci and Tch, Wuhan, Hubei, China
Jiangsu Province Hospital, Nanjing, Jiangsu, China
Tianjin Hematonosis Hospital, Tianjin, Tianjin, China
Cell Free DNA in Mature B-cell Lymphoma
Status: Recruiting
Last Changed: Sep 12, 2019
First Received: Sep 12, 2019
Disease(s): Mature B-Cell Lymphoma
Intervention(s): peripheral blood collection
Locations: Ruijin hospital, Shanghai, Shanghai, China
CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients
Status: Not yet recruiting
Last Changed: Feb 07, 2020
First Received: Feb 07, 2020
Disease(s): B-cell Lymphoma
Intervention(s): CD19/CD20 Dual-CAR-T cells
Locations: Hebei Yanda Ludaopei Hospital, Sanhe, Hebei, China